The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPressure Tech Regulatory News (PRES)

Share Price Information for Pressure Tech (PRES)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.50
Bid: 36.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.333%)
Open: 37.50
High: 37.50
Low: 37.50
Prev. Close: 37.50
PRES Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on FY22 Audit, AGM & Current Trading

21 Mar 2023 07:00

RNS Number : 5978T
Pressure Technologies PLC
21 March 2023
 

21 March 2023

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation (2014/596) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

 

Pressure Technologies plc

("Pressure Technologies", the "Group", or "the Company")

Update on FY22 Audit, AGM Resolutions and Current Trading

Pressure Technologies plc (AIM: PRES), the specialist engineering group, provides an update on the audit and the publication of its Annual Report & Accounts for the financial year ended 1 October 2022 ("FY22 Annual Report"), forthcoming AGM resolutions, and its current trading.

Audit Update

As part of the ongoing audit process in respect of the financial year ended 1 October 2022, the Board is now reviewing its accounting policy and past accounting treatment in respect of a small number of long-term defence contracts within its Chesterfield Special Cylinders division ("CSC").

Since FY19, the Group has consistently applied an accounting treatment whereby revenue for these specific defence contracts was recognised using an 'Output' methodology under IFRS 15, 'Revenue from Contracts with Customers' ("IFRS 15"), with costs being accrued to achieve a uniform profit margin throughout the multi-year life of the contracts, resulting in cost deferrals at financial period ends. Whilst this cost treatment impacted the timing of profit recognition between financial periods, it had no impact on either the total profitability of the contracts over their entire lives, nor the quantum or timing of cash flows.

The Company's auditor, Grant Thornton UK LLP ("Grant Thornton"), has advised the Company that this accounting treatment is not in compliance with IFRS 15, which requires that all costs incurred in the period relating to the contract should be immediately expensed. This means that cost deferral to achieve a uniform contract profit margin, as historically adopted by the Group, is not permitted.

Subject to final audit confirmation, as a result of a correct application of IFRS 15, the Group's results for FY22 are now expected to reflect a £1.2 million increase in operating losses over the £1.4 million adjusted operating loss1 as notified in the trading update on 15 November 2022. The correct application of IFRS 15 has also been applied to prior periods FY19, FY20 and FY21.  A restatement of the comparative period FY21 in the FY22 results will also be required, by which the previously reported operating loss2 of £0.7 million will increase by £0.8 million. Adjustments made to operating profit or loss in FY19 and FY20 are individually not material, but do result in a reduction to FY21 opening reserves of £0.3 million.

However, as a consequence, there will be a corresponding increase in operating profits of £2.3 million over the remaining lives of these contracts, the majority of which is expected to be in FY23 and FY24.

It is emphasised that these accounting adjustments only impact the timing of profit recognition under these specific contracts. They do not impact the expected net debt position of the Group as at 1 October 2022, the future cash generation profile of the Group, nor the underlying trading or operations of the business.

The Board's expectations for overall Group revenue of approximately £25 million in FY22 remains unchanged and as set out in the trading update on 15 November 2022.

Publication of FY22 Annual Report

Accordingly, Grant Thornton has advised that they will require additional time to complete the FY22 audit and, as a result, the Group is unlikely to publish its FY22 Annual Report ahead of the Annual General Meeting ("AGM") which is scheduled for 31 March 2023.

In the event that the FY22 Annual Report is not published by 31 March 2023, the Company's ordinary shares will be suspended from trading on AIM in accordance with AIM Rule 19 with effect from 7.30 a.m. on 3 April 2023, being the first business day after 31 March 2023. Suspension from trading will be lifted with the publication of the Annual Report, which will be as soon as possible and currently expected to be no later than the end of April 2023.

Annual General Meeting, Withdrawal of Resolutions

The Company will hold its AGM on Friday 31 March 2023 as previously announced. However, as a result of the expected delay to the publication of the FY22 Annual Report, the Board has decided to withdraw resolution 1 (relating to the approval of the FY22 Annual Report) and resolution 2 (relating to directors' remuneration) from the agenda of the AGM.

The withdrawal of resolutions 1 and 2 does not affect the validity of the Notice of AGM, the proxy form or any proxy votes already submitted in respect of the remaining resolutions to be proposed at the AGM. The numbering of all other proposed resolutions at the AGM remains unchanged. All arrangements for the AGM are unchanged from those previously notified.

The intention of the Board is that resolutions 1 and 2 will be the subject of a later General Meeting, which will be held as soon as reasonably practicable after publication of the FY22 Annual Report and subject to the notice requirements of the Company.

Trading Update

The Board remains confident in underlying market opportunities and continues to foresee a return to profitability and positive cash generation in FY23. The positive outlook for the Group in the medium and longer term is underpinned by a strong defence order book and pipeline, as most recently evidenced by the £18.2 million contract to supply air pressure vessels for a major UK naval new construction programme, announced on 6 February 2023. Also as noted above, compared to previous expectations, the results for FY23 and FY24 will benefit from a majority of the £2.3 million accounting treatment correction in respect of the long-term defence contracts within CSC. 

In addition, the current order book for the Precision Machined Components division is £4.3 million, its highest level since May 2020, with order intake from established international OEM customers expected to reach at least £2 million for the month of March 2023.

Banking Facility

The Group continues to make progress with the replacement of its existing Lloyds Bank credit facility3 with arrangements that provide greater flexibility and headroom. With support from Ernst & Young, the refinancing project has now progressed to detailed conversations with interested lender parties. In the meantime, Lloyds Bank remains supportive of the Group, which will repay a further £0.5 million of the drawn debt out of existing cash resources at the end of March 2023, reducing the drawn debt and facility level to £1.9 million. Gross borrowings less cash and cash equivalents as at the end of February 2023 was £0.9 million4.

Further announcements will be made in due course as appropriate.

 

Notes:

1. Operating loss before amortisation and exceptional administration charges. The trading update on 15 November 2022 referred to a potential downward impact to FY22 operating loss of c.£0.5 million due to 'FY17 to FY21 contract margin adjustments'. The correction of contract accounting treatment described in this announcement has superseded the previously disclosed historic contract margin adjustments.

2. Operating loss before amortisation, impairments and exceptional administration charges.

3. The current credit facility with Lloyds Bank runs to 31 March 2024.

4. Excludes asset finance leases of £1.1 million and right-of-use asset leases of £1.4 million at the end of February 2023.

 

The person responsible for arranging the release of this announcement on behalf of Company is Chris Walters, Chief Executive. 

For further information, please contact:

Pressure Technologies plc

Chris Walters, Chief Executive

Tel: 0330 015 0710

PressureTechnologies@houston.co.uk

Singer Capital Markets (Nomad and Broker)

Rick Thompson / Asha Chotai

Tel: 0207 496 3000

Houston (Financial PR and Investor Relations)

Kay Larsen / Ben Robinson

Tel: 0204 529 0549

COMPANY DESCRIPTION

www.pressuretechnologies.com

With its head office in Sheffield, Pressure Technologies was founded on its leading market position as a designer and manufacturer of high-integrity, safety-critical components and systems serving global supply chains in oil and gas, defence, industrial and hydrogen energy markets.

The Company has two divisions, Chesterfield Special Cylinders and Precision Machined Components.

Chesterfield Special Cylinders (CSC) - www.chesterfieldcylinders.com

● Chesterfield Special Cylinders, Sheffield, includes CSC Deutschland GmbH.

Precision Machined Components (PMC) - www.pt-pmc.com

● Precision Machined Components includes the Al-Met, Roota Engineering and Martract sites.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEIEDSEDSEFD
Date   Source Headline
10th Dec 20204:42 pmRNSHolding(s) in Company
9th Dec 202011:21 amRNSHolding(s) in Company
7th Dec 20204:43 pmRNSHolding(s) in Company
7th Dec 20203:49 pmRNSHolding(s) in Company
4th Dec 20202:36 pmRNSHolding(s) in Company
3rd Dec 202010:55 amRNSHolding(s) in Company
1st Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
30th Nov 20204:36 pmRNSPrimaryBid Offer
30th Nov 20204:35 pmRNSProposed Placing and PrimaryBid Offer
3rd Nov 20207:00 amRNSFull Year Trading Update
21st Oct 20207:00 amRNSBoard Changes
30th Sep 20207:00 amRNSMajor Contracts and Trading Update
20th Aug 20207:00 amRNSBoard Changes
24th Jul 20204:26 pmRNSGrant of Share Options
3rd Jul 20207:35 amRNSDisposal of equity holding in Greenlane Renewables
23rd Jun 20207:01 amRNS2020 Interim Results
23rd Jun 20207:00 amRNSBoard changes
16th Apr 20202:08 pmRNSDirector Shareholding
14th Apr 20201:09 pmRNSDirector Shareholding
9th Apr 20207:00 amRNSUPDATE ON TRADING AND COVID-19 IMPACT
17th Mar 20207:00 amRNSDirector Shareholding
13th Mar 20207:00 amRNSDirector Shareholding
5th Mar 20207:00 amRNSResult of AGM
28th Feb 20203:00 pmRNSDirector Shareholding
25th Feb 202011:15 amRNSFurther re: Proposed Offering by Greenlane
19th Feb 20207:00 amRNSDirector Shareholding
12th Feb 20207:00 amRNSFurther re: Proposed Offering by Greenlane
11th Feb 20204:40 pmRNSDirector Shareholding
11th Feb 20207:00 amRNSProposed offering by Greenlane Renewables Inc.
10th Feb 202011:19 amRNSPurchase of shares by a Director
30th Jan 20207:00 amRNSPublication of Annual Report and Notice of AGM
28th Jan 20207:00 amRNSBoard Change
23rd Jan 20207:00 amRNSBoard Changes
13th Jan 20203:36 pmRNSOutcome of Sentencing Hearing
17th Dec 20197:00 amRNSPreliminary Results
5th Dec 20197:00 amRNSPostponement of Sentencing
27th Nov 20197:00 amRNSTrial Verdict
21st Nov 20197:00 amRNSNotice of Results and Trading Update
18th Nov 20197:00 amRNSCommencement of Trial
9th Oct 20197:00 amRNSMajor Contract Win with EDF Energy
25th Jun 20197:00 amRNS2019 Interim Results
7th Jun 20197:00 amRNSNew Adviser Appointments and Interim Results date
6th Jun 20194:30 pmRNSDirectorate Change
4th Jun 20197:00 amRNSCompletion of the sale of Greenlane Biogas
28th May 20197:00 amRNSUpdate on the proposed sale of Greenlane Biogas
13th May 201912:31 pmRNSDevelopment in the proposed sale of Greenlane
30th Apr 20193:22 pmRNSHolding(s) in Company
1st Apr 20197:25 amRNSUpdate on the proposed sale of Greenlane Biogas
27th Mar 20196:20 pmRNSHolding(s) in Company
26th Mar 20195:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.